Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea

PURPOSE: The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti–programmed death cell protein 1 antibody licensed for the treatment of locally adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Sun Min, Kim, Sang-We, Cho, Byoung Chul, Kang, Jin Hyung, Ahn, Myung-Ju, Kim, Dong-Wan, Kim, Young-Chul, Lee, Jin Soo, Lee, Jong-Seok, Lee, Sung Yong, Park, Keon Uk, An, Ho Jung, Cho, Eun Kyung, Jang, Tae Won, Kim, Bong-Seog, Kim, Joo-Hang, Lee, Sung Sook, Na, Im-II, Yoo, Seung Soo, Lee, Ki Hyeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577826/
https://www.ncbi.nlm.nih.gov/pubmed/32599984
http://dx.doi.org/10.4143/crt.2020.245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577826/
https://www.ncbi.nlm.nih.gov/pubmed/32599984
http://dx.doi.org/10.4143/crt.2020.245

Ejemplares similares